Search Results

Conduit Pharmaceuticals Inc., announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024.

Avadel Pharmaceuticals plc announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

InDex Pharmaceuticals Holding AB announced that remaining commitments for the company have been quantified, and the expected cash balance per March 31, 2024, amounts to SEK 180-190 million.

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research with a focus on healthy aging, announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

Invivyd, Inc., a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets.

INOVIO announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

Aileron Therapeutics, Inc. announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

InDex Pharmaceuticals Holding AB will attend the United European Gastroenterology Week, one of the world’s leading gastroenterology congresses.

InDex Pharmaceuticals Holding AB announces that an independent DMC has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE.

Skye Bioscience, Inc. today announced the Company has been included in the Russell 2000 ® Index and the broad-market Russell 3000 ® Index, effective at the U.S. market open on July 1, 2024.